The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | What does the future hold for T-cell engagers in small cell lung cancer?
Giannis Mountzios, MD, Henry Dunant Hospital, Athens, Greece, discusses the potential of T-cell engagers, including tarlatamab, in the first-line setting for small cell lung cancer (SCLC). Ongoing clinical trials are currently evaluating other T-cell engagers, including tri-specific T-cell engagers, with chemotherapy or as consolidation treatment after induction chemoimmunotherapy, as well as in maintenance settings with immune checkpoint inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a very important question and currently T-cell engagers are being evaluated in the first-line setting. So we are really looking forward to the advent of those agents in the first-line setting in an effort to further improve the outcomes for our patients. So we now have a current array of clinical trials, not only with tarlatamab, but also with other T-cell engagers, and some of them being tri-specific T-cell engagers that are being evaluated either with chemotherapy in the first-line setting or as a consolidation treatment after induction chemoimmunotherapy in the maintenance treatment, in the maintenance setting, together with immune checkpoint inhibitors...
This is a very important question and currently T-cell engagers are being evaluated in the first-line setting. So we are really looking forward to the advent of those agents in the first-line setting in an effort to further improve the outcomes for our patients. So we now have a current array of clinical trials, not only with tarlatamab, but also with other T-cell engagers, and some of them being tri-specific T-cell engagers that are being evaluated either with chemotherapy in the first-line setting or as a consolidation treatment after induction chemoimmunotherapy in the maintenance treatment, in the maintenance setting, together with immune checkpoint inhibitors. And importantly, we are also seeing a number of those trials incorporating also other high-grade neuroendocrine tumors, for example, extra-pulmonary neuroendocrine tumors, which also have a high expression of DLL3.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
